Tel Aviv University and BioNTech RNA Pharmaceuticals GmbH announced that they have entered into a license agreement to further explore a set of novel lipids for improved mRNA delivery in various therapeutic indications. Under the terms of the agreement, BioNTech gains full access to an undisclosed number of lipids developed by Professor Dr. Dan Peer, Managing Director Center for Translational Medicine and Chair Cancer Biology Research Center at Tel Aviv University, for use in ribonucleic acid (RNA) formulations. Financial terms of the agreement were not disclosed. The lipids developed by Prof. Peer provide delivery solutions for all nucleic acid-based therapies and enable as well the entrapment of payloads with very large molecular mass (over 10Kb).